Genoway Cash Flow Conversion Efficiency
Genoway cash flow conversion efficiency. Based on the latest financial reports, Genoway (ALGEN) has a cash flow conversion efficiency ratio of -0.152x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.80 Million ≈ $-3.27 Million USD) by net assets (€18.39 Million ≈ $21.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Genoway (2009–2024)
Cash flow conversion efficiency of Genoway from 2009 to 2024. This chart illustrates how Genoway's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALGEN stock price and chart for real-time trading data and today's change.
Genoway Cash Flow Conversion Ratio Explained
Genoway cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Genoway Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genoway ranked by their cash flow conversion efficiency. Also see market value of Genoway for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
T S Flour Mill Public Company Limited
BK:TMILL
|
0.298x |
|
Shandong Chenming Paper Holdings Limited
F:SCD1
|
0.823x |
|
Mahindra EPC Irrigation Limited
NSE:MAHEPC
|
-0.056x |
|
Taya Inv-L
TA:TAYA
|
0.002x |
|
HPP Holdings Bhd
KLSE:0228
|
0.034x |
|
Berlina Tbk
JK:BRNA
|
0.000x |
|
S. Khonkaen Foods Public Company Limited
BK:SORKON
|
0.071x |
|
Kiattana Transport Public Company Limited
BK:KIAT
|
0.045x |
Annual Cash Flow Conversion Efficiency for Genoway (2009–2024)
The table below shows the annual cash flow conversion efficiency of Genoway from 2009 to 2024. Review ALGEN free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €18.57 Million ≈ $21.72 Million |
€5.38 Million ≈ $6.29 Million |
0.290x | +64.41% |
| 2023-12-31 | €17.38 Million ≈ $20.32 Million |
€3.06 Million ≈ $3.58 Million |
0.176x | +20.96% |
| 2022-12-31 | €16.17 Million ≈ $18.90 Million |
€2.36 Million ≈ $2.75 Million |
0.146x | +477.82% |
| 2021-12-31 | €14.56 Million ≈ $17.02 Million |
€-561.34K ≈ $-656.27K |
-0.039x | -111.14% |
| 2020-12-31 | €9.00 Million ≈ $10.52 Million |
€-164.33K ≈ $-192.11K |
-0.018x | -110.59% |
| 2019-12-31 | €6.84 Million ≈ $8.00 Million |
€1.18 Million ≈ $1.38 Million |
0.172x | +60.68% |
| 2018-12-31 | €7.89 Million ≈ $9.22 Million |
€847.03K ≈ $990.27K |
0.107x | +24.32% |
| 2017-12-31 | €7.19 Million ≈ $8.41 Million |
€620.94K ≈ $725.94K |
0.086x | +150.36% |
| 2016-12-31 | €5.26 Million ≈ $6.15 Million |
€-901.83K ≈ $-1.05 Million |
-0.171x | -194.23% |
| 2015-12-31 | €4.68 Million ≈ $5.47 Million |
€851.08K ≈ $995.00K |
0.182x | +367.50% |
| 2014-12-31 | €5.15 Million ≈ $6.02 Million |
€200.29K ≈ $234.16K |
0.039x | -76.71% |
| 2013-12-31 | €5.10 Million ≈ $5.97 Million |
€852.87K ≈ $997.09K |
0.167x | +147.59% |
| 2012-12-31 | €4.84 Million ≈ $5.66 Million |
€-1.70 Million ≈ $-1.99 Million |
-0.351x | -347.79% |
| 2011-12-31 | €5.23 Million ≈ $6.12 Million |
€741.51K ≈ $866.90K |
0.142x | -28.72% |
| 2010-12-31 | €4.60 Million ≈ $5.37 Million |
€914.07K ≈ $1.07 Million |
0.199x | -57.80% |
| 2009-12-31 | €3.82 Million ≈ $4.47 Million |
€1.80 Million ≈ $2.11 Million |
0.471x | -- |
About Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines… Read more